HomeCompareEMITF vs ORCC

EMITF vs ORCC: Dividend Comparison 2026

EMITF yields 111.11% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EMITF wins by $6.05M in total portfolio value
10 years
EMITF
EMITF
● Live price
111.11%
Share price
$1.80
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.07M
Annual income
$2,192,447.17
Full EMITF calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — EMITF vs ORCC

📍 EMITF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEMITFORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EMITF + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EMITF pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EMITF
Annual income on $10K today (after 15% tax)
$9,444.44/yr
After 10yr DRIP, annual income (after tax)
$1,863,580.09/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, EMITF beats the other by $1,863,579.21/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EMITF + ORCC for your $10,000?

EMITF: 50%ORCC: 50%
100% ORCC50/50100% EMITF
Portfolio after 10yr
$3.05M
Annual income
$1,096,224.10/yr
Blended yield
35.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

EMITF
No analyst data
Altman Z
-0.0
Piotroski
3/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EMITF buys
0
ORCC buys
0
No recent congressional trades found for EMITF or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEMITFORCC
Forward yield111.11%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$6.07M$21.4K
Annual income after 10y$2,192,447.17$1.04
Total dividends collected$5.48M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: EMITF vs ORCC ($10,000, DRIP)

YearEMITF PortfolioEMITF Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$21,811$11,111.11$11,190$489.61+$10.6KEMITF
2$45,987$22,649.13$12,229$256.01+$33.8KEMITF
3$93,836$44,629.82$13,216$130.74+$80.6KEMITF
4$185,513$85,108.97$14,207$66.02+$171.3KEMITF
5$355,752$157,252.56$15,234$33.17+$340.5KEMITF
6$662,484$281,829.11$16,317$16.62+$646.2KEMITF
7$1,199,347$490,489.82$17,468$8.32+$1.18MEMITF
8$2,113,183$829,881.38$18,695$4.16+$2.09MEMITF
9$3,627,652$1,366,546.40$20,006$2.08+$3.61MEMITF
10$6,074,035$2,192,447.17$21,407$1.04+$6.05MEMITF

EMITF vs ORCC: Complete Analysis 2026

EMITFStock

Elbit Imaging Ltd., together with its subsidiaries, engages in the development, production, and marketing of therapeutic medical systems for performing non-invasive treatments on the human body in the North and South America, Europe, Asia, and Oceania. The company offers treatment-oriented medical systems with ultrasound beam and magnetic resonance imaging for noninvasive treatments in human body. It also offers medical products based on stem cells derived primarily from umbilical cord blood and intended for bone marrow transplantation in patients with leukemia or lymph node cancer, non-malignant blood diseases, and metabolic genetic diseases. In addition, the company is involved in the sale of plots and villas in India. The company was incorporated in 1996 and is headquartered in Petach Tikva, Israel.

Full EMITF Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this EMITF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EMITF vs SCHDEMITF vs JEPIEMITF vs OEMITF vs KOEMITF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.